Overview

Gender

male

Investor Type

Investment Partner

Bernard Gilly is the Founder and Chief Executive Officer at Brainever. He has been Chairman and CEO of Fovea Pharmaceuticals, a biotech company he founded in 2005 and which he sold in 2009 to Sanofi in a 370M€ transaction and then became Senior Vice-President of the Ophthalmology Division of Sanofi until March 2012.
Prior to Fovea, Bernard was a Partner at Sofinnova Partners from 2000 to November 2005. He founded and invested in several companies, including Sequoia Pharmaceuticals (USA), Faust Pharmaceuticals (France) and Cellzome (Germany).

Prior to joining Sofinnova, Bernard has been President and CEO of Transgene, a company he had driven from its early financing round in 1994 to its listing on the Nasdaq and the Nouveau Marche in March 1998, successfully raising a total of 160M€. He was able to sign two key strategic partnerships with Schering-Plough and with Human Genome Sciences.
Prior to joining Transgene, Bernard spent 6 years as VP R&D at Pasteur-Merieux-Connaught, the vaccine company that since then became Sanofi Pasteur. He was managing 1200 scientists and development engineers in three main facilities (France, USA and Canada) and was a member of the Executive Committee of the group.